GSK buys GlycoVaxyn for $212 mln
Sofinnova Partners has sold GlycoVaxyn to GlaxoSmithKline for $212 million. Schlieren, Switzerland-based GlycoVaxyn develops conjugate vaccines to treat bacterial infections. GSK was a minority investor of GlycoVaxyn.
11 February 2015•2 mins read
